Purpose: To describe the clinical and genetic features of a Chinese progressive myoclonus epilepsy (PME) patient related with SCARB2 mutation without renal impairment and review 27 SCARB2-related PME patients from 11 countries. Methods: The patient was a 27-year-old man with progressive action myoclonus, ataxia, epilepsy, dysarthria and absence of cognitive deterioration. Renal functional test was normal. Electroencephalography (EEG) showed progressively slowed background activity and sporadic generalized spike-and-wave discharges. Electromyography (EMG) showed slowed motor and sensory nerve conduction velocities and distal motor latency delay accompanied by normal compound motor action potential (CMAP) and amplitudes of sensory nerve action potential (SNAP). The amplitude of cortical components of brainstem auditory-evoked potential (BAEP) was normal with slightly prolonged latencies. Generalized atrophy, ventricle enlargement and white matter degeneration was observed in brain magnetic resonance imaging (MRI). Open muscle biopsy and genetic analysis were performed. Two hundred healthy individuals were set for control. Quantitative real time PCR (qPCR), western blotting and immunofluorescence were carried out to evaluate the fate of the SCARB2 mRNA and lysosomal-membrane type 2 (LIMP2) protein level. Results: One homozygous mutation in SCARB2 gene (c.1187 + 5G > T) was identified in the patient. Each of his parents carried a heterozygous variant. This mutation was not detected among the healthy controls and predicted to be damaging or disease causing by prediction tools. qPCR revealed a significantly lower level of SCARB2 mRNA in peripheral blood cell of the proband compared with his parents and healthy control individuals. Muscle biopsy showed mild variation in fiber size. Western blotting and immunofluorescence detected an extremely weak signal of LIMP2 protein from skeletal muscle of the proband. Conclusion: In this study, we identified a SCARB2-related PME patient with normal renal function and a novel homozygous splicing mutation. SCARB2 gene should be analyzed in patients with progressive action myoclonus, epilepsy, peripheral neuropathy, without cognitive deterioration or renal failure.
Introduction
The progressive myoclonus epilepsies (PME) are a diverse group of genetic neurodegenerative diseases characterized by abnormal myoclonus, epileptic seizures and variable degrees of neurologic dysfunction, with debilitating evolution, resistance to treatment and poor prognosis [1, 2] . Action myoclonus-renal failure syndrome (AMRF, OMIM 254900) is a rare autosomal recessive disorder with progressive myoclonus, dysarthria, ataxia, generalized seizure and absence of intellectual impairment. SCARB2 has been confirmed as the causative gene of AMRF [3, 4] . However, SCARB2-related PME is not always presenting with renal dysfunction. Thus, SCARB2-deficiency could be divided into two groups: PME with renal failure (AMRF) or without renal failure [5] [6] [7] [8] . The syndrome is considered to be related to loss-of-function mutations in SCARB2 which encodes lysosomal-membrane type 2 protein (LIMP2), a member of the CD36 scavenger receptor-like protein superfamily [9, 10] . LIMP2 is a 478 amino acid transmembrane protein mainly expressed in lysosomes and late endosomes, which plays a critical role in b-glucocerebrosidase (b-GC) trafficking from the endoplasmic reticulum to the lysosome [10, 11] . Mutations that impair LIMP2 interacting with b-GC or the biogenesis and maintenance of the lysosomal and endosomal compartment cause progressive myoclonus epilepsy. In the past two decades, 19 unrelated families with a recessive PME caused by SCARB2 gene mutations have been described.
Here, we describe a Chinese PME patient with novel splicing mutation in intron 9 of SCARB2, characterized by progressive myoclonus, generalized seizures, ataxia, demyelinating polyneuropathy, without renal involvement or cognitive impairment.
Methods

Ethical approval
The Ethics Committee of Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, approved the study. All participants provided written informed consent.
Patient
We identified a Han Chinese patient fulfilled the clinical diagnosis of PME. A family (Fig. 1A) with consanguineous history was included in this study. The patient and his family members were clinically examined.
Mutation analysis
Blood samples were taken from the proband and 3 family members. Unaffected individuals (n = 200) of matched geographic ancestry were also included as healthy controls. The protocols were all approved by the Rui Jin Hospital Ethics Committee, Shanghai Jiao Tong University School of Medicine. Genomic DNA was extracted from 3 ml peripheral blood samples by a standard protocol using QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). Epilepsy panel was performed on genomic DNA from the patient. The sequence variant was further interpreted and classified according to the American College of Medical Genetics and Genomics (ACMG) Standards and Guidelines [12] . During this session, two neurogeneticists further analyzed the allele frequency (1000 g, ESP6500, dbSNP, ExAC-East Asian and 200 in-house ethnically matched healthy controls), pathogenicity prediction [Human Splicing Finder (http://www.umd.be/HSF3/index.html) and Mutationtaster (http://www.mutationtaster.org)], relation of the gene to disease, and inheritance pattern. Putative pathogenic variant was further confirmed by Sanger sequencing both the forward and reverse strands. T-test analysis demonstrated that mRNA levels in the proband were significantly lower than the controls (7.24%, p < 0.01). E. Detection of LIMP2 proteins of muscle tissues from the proband and normal control in western blotting showed mutant LIMP2 was significantly weaker than normal control group. F. Detection of LIMP2 protein in muscle frozen-section from normal control (top panel) and the proband (bottom panel) by immunofluorescence microscopy.
Quantitative real time PCR (qPCR)
Total RNA was extracted from peripheral blood cells using a standard method with TRIZOL Reagen (Invitrogen), and reversetranscribed using the PrimeScript 1 RT reagent Kit (Takara) according to the manufacture's instruction. To determine whether the SCARB2 variant affects the splice site, we designed three pairs of primers (Table 2) , namely 6F/7R (at exon 6 and 7, respectively), 7F/8R (at exon 7 and 8, respectively) and 8F/11R (at exon 8 and 11, respectively) to verify the amount of SCARB2 mRNA.
Muscle biopsy and immunofluorescence
An open muscle biopsy was performed on the left biceps brachii in the patient. The tissue was frozen and then cut at 7-mm sections. These sections were stained according to standard histological and enzyme histochemical procedures with hematoxylin and eosin (HE), modified Gomori Trichrome, periodic acidic Schiff, oil red O, nicotinamide adenine dinucleo-tide tetrazolium reductase, succinate dehydrogenease, cytochrome C oxidase, and esterase. Immunofluorescence was applied using antibody against LIMP2 at a dilution of 1:100 (SAB3500449, Sigma).
Western blotting
Protein was extracted from muscle tissue lysate and the expression level of LIMP2 was detected by western blotting with anti-LIMP2 antibody (SAB3500449, Sigma).
Results
Clinical findings
The patient from the mainland of China was a 27-year-old man evaluated for progressive unsteadiness of gait and repeated episodes of falling for 8 years. His elder sister was normal. Their parents were first cousins (Fig. 1A) . At the age of 19 years, the proband started to present with a mild, intermittent upper limb tremor occurring only with action and exacerbated by stress. At the same time, he developed clumsiness in the lower limbs, mild gait instability and difficulties in running or jumping. Since then, he had recurrent falls and occasional jerks without loss of consciousness, particularly when nervous and performing movements. Gradually, multifocal action myoclonus appeared, which was reflex-sensitive to touch on distal extremities and worsened by anxiety and fatigue. At age 20, his neurologic examination showed scanning speech, brisk tendon reflexes, broad-based gait, severe action myoclonus, ataxia and myokymia, without nystagmus. The muscle tone and strength was normal. Generalized tonic-clonic seizures were noticed at the age of 21 both diurnally and nocturnally. Since then, his myoclonus became worse which was triggered by movement and reflex-sensitive to tactile, auditory and visual stimuli (Video 1). Disabling action myoclonus was partially responsive to clonazepam (4 mg, three times daily). However, frequent seizures were resistant to multiple anti-epileptic drugs, including valproate (500 mg, twice daily), phenobarbital (30 mg, daily) and piracetam (800 mg, three times daily). His mental status and renal function was preserved and remained stable. At the age of 26, he was wheelchair-bound.
At age 20, 22, 26 and 27, routine laboratory tests were always unremarkable with normal serum creatinine and renal functional examinations. Electroencephalography (EEG) examinations showed progressively slowed background with irregular theta and delta activity intermixed with alpha activity and sporadic generalized spike-and-wave discharges during wakefulness. Electromyography (EMG) demonstrated slowed motor and sensory nerve conduction velocities in lower limbs (MCV: 37.2-38.8 m/s, SCV: 33.2-35.0 m/s), distal motor latency delay, normal compound motor action potential (CMAP) and amplitudes of sensory nerve action potential (SNAP), slightly prolonged latencies of cortical components of brainstem auditory-evoked potentials (BAEP), moderately enlarged latency of pattern reversal visual evoked potential (Pr-VEP) and abnormal somatosensory evoked potentials (SEP). Magnetic resonance imaging (MRI) revealed marked atrophy in cerebellum, brainstem, corpus callosum and hippocampus with ventrical enlargement and mild degeneration of white matter around bilateral posterior ventricles (Fig. 1C) . Muscle biopsy showed mild variation in fiber size.
Genetic findings
A novel homozygous variant c.1187 + 5G > T (IVS9 + 5G > T) in SCARB2 gene was identified in the proband. His parents and elder sister were heterozygous carriers (Fig. 1B) . This variant was neither found in 200 healthy controls nor reported in 1000 Genome Project (http://browser.1000genomes.org), NHLBI Exome Sequencing Project (ESP) Exome Variant Server (http://evs.gs.washington. edu/EVS), Exome Aggregation Consortium (ExAC) and dbSNP Fig. 2 . Gene structure of SCARB2 gene and SCARB2 mutations in 27 PME patients with/without renal failure described here and reported previously. 
Functional evidence
The results of qPCR using the primers 8F/11R, showed that a reduced mRNA level of SCARB2 gene existed in the patient compared with his parents and healthy controls (Fig. 1D) : the parents were about half of the control, and the proband was even lower. As to the primers 6F/7R or 7F/8R, the examination of qPCR showed similar results. In western blotting, protein extracts from skeletal muscle of healthy control showed a strong signal at $85 kDa while a significantly weaker signal was detected from the patient (Fig. 1E) . Under confocal microscopy, LIMP2 protein expressed in the skeletal muscle showed remarkable reduced fluorescence intensity in the proband's muscle as compared to control (Fig. 1F ).
Discussion
We describe a Chinese patient presenting progressive myoclonic epilepsy without renal failure due to a SCARB2 mutation (c.1187 + 5G > T). His parents and sister each carrying one heterozygous variant were not clinically affected. The result of qPCR disclosed significant mRNA decay due to a splicing mutation, causing LIMP2 deficiency in protein amount which was further confirmed by western blotting and immunofluorescence.
To date, twenty SCARB2 mutations were identified among 27 patients from 20 families (including this study) diagnosed as SCARB2-related progressive myoclonus epilepsy with or without renal failure (Fig. 2 (Table 1) [3] [4] [5] [6] [7] [8] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The mean age of onset was 22.0 AE 9.8 years (range 9 to 52 years). Symptoms were characterized by tremor in limbs (25/27), action myoclonus (27/ 27), ataxia (26/27), epileptic seizures (24/27), normal cognitive function (23/27) and dysarthria (21/27). Individuals with normal and impaired renal function took almost equal share of the totality (13/27 vs 14/27). Renal function involvement was documented in 14 patients with various severity ranging from mild proteinuria to renal failure. Ocular movement abnormalities were reported in 5 out of 27 patients. In 9/27 patients, mild to moderate brain atrophy had been observed. Electrophysiologically, the patients who underwent EEG examinations exhibited photosensitive epileptogenic abnormality with/without slowed background activity. Among the 13 patients with EMG examinations, 8 had electrophysiological and/or clinical evidence of polyneuropathy. The study in SCARB2 knockout mice detected a remarkable loss of peripheral myelin proteins as well as the upregulated lysosomal enzymes in LIMP2-deficient Schwann cells, suggesting that the lysosomal compartment is associated with SCARB2-related myelination disorder [23] . These findings suggest that polyneuropathy may be a part of SCARB2 deficiency. In addition to PME-SCARB2, a number of conditions may be associated with a case of peripheral neuropathy and myoclonus, such as mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), celiac disease, spinocerebellar ataxia type 6 (SCA6) and so on. However, these 8 patients did not harbor evidence of the disorders mentioned above. As to the treatment of SCARB2-related PME, antiepileptic therapy usually could not satisfactorily control the epileptic seizures even with multiple drugs at conventional doses (17/17) . In addition, a mild to moderate improvement of action myoclonus was recognized with anti-myoclonic treatment (10/10). With regard to the renal dysfunction, 3/14 patients underwent dialysis, 3/14 with renal transplant. Yet neither dialysis nor renal transplantation was effective for the neurological condition, which progressed even with normalized renal function.
LIMP2 protein contains a total of 5 domains. The topological domain N-terminus (residues 1-4), transmembrane domain I (residues 5-27), luminal domain (residues 28-433), transmembrane domain II (residues 434-459) and C-terminus cytoplasmic domain (residues 460-478). A leucine-isoleucine motif within the C-terminal cytoplasmic tail, interacts with the heterotetrameric adaptor-complex 3 (AP3) and has been proposed to be responsible for the lysosomal localization of LIMP2 [24] . Among all of the 20 mutations, 7 mutations were located on splicing sites (Intron 3, 5, 8, 9 and 10) and the other 13 in exons (Exon 1, 3, 4, 5, 7, 8 and 11). For the latter part, 10 out of 13 mutations were located on luminal domain, two on transmembrane domain II and one on C-terminal cytoplasmic tail of the LIMP-2 protein. Interestingly, there was only 1 missense mutation among the twenty mutations identified, while the other 19 were frameshift or splicing ones. This supported protein insufficiency and/or loss of function might be the most prevalent pathological mechanism of SCARB2-PME. In addition, more attention should be paid to splicing sites, small insertion or deletion when analyzing the sequencing data of SCARB2 gene. However, we did not discover clear genotype-phenotype correlations, suggesting evidently clinical heterogeneity existed in this group of patients.
Conclusion
The present study identified one Chinese patient with PME caused by novel homozygous splicing mutation in the SCARB2 gene. This study further emphasized the importance of SCARB2 screened for the patients manifesting as PME and demyelinating polyneuropathy without intellectual impairment or renal failure.
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